GTHX G1 Therapeutics, Inc.

24.680.58 (+2.41%)
Close: December 13, 2019

26.001.32 (+5.35%)
After hours

Quote

Previous Close
$24.68
Day Range
$23.80-$25.14
52 Week Range
$13.87-$41.80
Volume
355,082
Avg Volume
300,248
Dividend TTM
-
Ex-Dividend Date
-

Valuation

Market Cap
$927.52M
Enterprise Value (EV)
$536.44M
PE Ratio
-
EV/EBITDA
-6.02
Price/Sales
-
Price/Book
2.58
PEG Ratio
0.18

Financials

Revenue
-
Gross Profit
-$175.00K
EBITDA
-$89.11M
EPS, ttm
-$2.97
Profit Margin
-
Revenue/Employee
-
Next Earnings Date
2/18/2020 (66 days)
Debt to Equity
-
Debt
-
Cash
$369.29M
Net Debt
-

Performance

Beta
2.38
200 Day Moving Avg
$24.28
50 Day Moving Avg
$22.25
52 Week Change
-19.11%
YTD Change
28.58%
1 Month Change
11.02%
3 Month Change
-31.97%
6 Month Change
32.83%
1 Year Change
-19.11%
2 Year Change
21.72%
5 Year Change
60.67%

Share Count

Shares Outstanding
37.6M
Float
30.2M
Restricted Shares
7.4M
Restricted Shares, %
19.58%

G1 Therapeutics, Inc. Company Details

Sector: Health Technology

Industry: Pharmaceuticals: Major

CEO: Mark A. Velleca

Website: http://www.g1therapeutics.com

Description: G1 Therapeutics, Inc. develops drugs for cancer treatment. It is a clinical-stage biopharmaceutical company that focuses on the discovery and development of novel therapies to address significant unmet needs in oncology. The company was founded by Kwok-Kin Wong and Norman E. Sharpless on May 19, 2008 and is headquartered in Research Triangle Park, NC.

Employees: 84